Translate AMICOR contents if you like

Showing posts with label Alzheimer. Show all posts
Showing posts with label Alzheimer. Show all posts

Wednesday, July 29, 2020

Alzheimer Disease


Flu, pneumonia vaccines linked to reduced risk of Alzheimer's
International investigators, clinicians and care researchers gathered virtually this week for the Alzheimer's Association International Conference® 2020 (AAIC®) to discuss the latest studies, theories and discoveries that will help bring the world closer to breakthroughs in dementia science. Studies presented at AAIC suggest flu and pneumonia vaccinations — especially multiple vaccinations over time — are associated with a lower risk of Alzheimer's in later life.

Click here to read more
Studies show blood tests for Alzheimer's might be on the horizon
Multiple studies reported at AAIC showed advances in blood tests for abnormal versions of the Alzheimer's-related protein tau. A blood test has the potential to make diagnosis simpler, more affordable and widely available.
Click here to read more

New study announced to understand impact of COVID-19 on the brain
The COVID-19 pandemic continues to create additional challenges for people living with Alzheimer's and all dementia, their families and caregivers. At AAIC, the Alzheimer's Association announced a new research study to globally track and understand the long-term impact of the novel coronavirus on the brain.
Click here to read more

Wednesday, July 22, 2020

Alzheimer and Infections

June 8, 2020

Can Infections Cause Alzheimer Disease?

JAMA. 2020;324(3):239-240. doi:10.1001/jama.2020.4085
Anew model of the pathogenesis of Alzheimer disease (AD) is challenging the old. New disease models do not always replace old models. Instead, the new sometimes completes the old.
The Old Model
Amyloid-β, Tau, and APOE
The pathogenesis of Alzheimer disease (AD) remained a mystery for 80 years. However, in recent decades, 3 molecules have been found to play crucial roles: amyloid-β (Aβ), found in plaques; tau, found in neurofibrillary tangles; and apolipoprotein E (APOE).1 Individuals who carry 2 copies of the allele for APOE*E4 are about 10 times more likely to develop the disease than those who have no copies of this allele./.../

Wednesday, July 08, 2020

aducanumab


Biogen submits aducanumab data for FDA review
Biogen announced the completion of its regulatory filing to the U.S. Food and Drug Administration (FDA) on aducanumab for the treatment of dementia and mild cognitive impairment due to Alzheimer's. If approved, aducanumab would become the first therapy to reduce the cognitive and functional decline of people living with the disease.

Click here to read more

Tuesday, June 30, 2020

Alzheimer's plaque

Study pinpoints Alzheimer’s plaque emergence early and deep in the brain

Long before symptoms like memory loss even emerge, the underlying pathology of Alzheimer’s disease, such as an accumulation of amyloid protein plaques, is well underway in the brain. A longtime goal of the field has been to understand where it starts so that future interventions could begin there.
A new study by MIT neuroscientists at The Picower Institute for Learning and Memory could help those efforts by pinpointing the regions with the earliest emergence of amyloid in the brain of a prominent mouse model of the disease. Notably, the study also shows that the degree of amyloid accumulation in one of those same regions of the human brain correlates strongly with the progression of the disease.
“Alzheimer’s is a neurodegenerative disease so in the end you can see a lot of neuron loss,” said Wen-Chin “Brian” Huang, co-lead author of the study and a postdoc in the lab of co-senior author Li-Huei Tsai, Picower Professor of Neuroscience and director of the Picower Institute. “At that point it would be hard to cure the symptoms. It’s really critical to understand what circuits and regions show neuronal dysfunction early in the disease. This will in turn facilitate the development of effective therapeutics.”
In addition to Huang, the study’s co-lead authors are Rebecca Canter, a former member of the Tsai lab, and Heejin Choi, a former member of the lab of co-senior author Kwanghun Chung, associate professor of chemical engineering and a member of the Picower Institute and the Institute for Medical Engineering and Science.
Tracking plaques
Many research groups have made progress in recent years by tracing amyloid’s path in the brain using technologies such as positron emission tomography and by looking at brains post-mortem, but the new study in Communications Biology adds substantial new evidence from the 5XFAD mouse model because it presents an unbiased look at the entire brain as early as one month of age. The study reveals that amyloid begins its terrible march in deep brain regions such as the mammillary body, the lateral septum and the subiculum before making its way along specific brain circuits that ultimately lead it to the hippocampus, a key region for memory, and the cortex, a key region for cognition.
The team used SWITCH, a technology developed by Chung, to label amyloid plaques and to clarify the whole brains of 5XFAD mice so that they could be imaged in fine detail at different ages. The team was consistently able to see that plaques first emerged in the deep brain structures and then tracked along circuits such as the Papez memory circuit to spread throughout the brain by 6-12 months (a mouse’s lifespan is up to three years).
The findings help to cement an understanding that has been harder to obtain from human brains, Huang said, because post-mortem dissection cannot easily account for how the disease developed over time and PET scans don’t offer the kind of resolution the new study provides from the mice.
Key validations
Importantly, the team directly validated a key prediction of their mouse findings in human tissue: If the mammillary body is indeed a very early place that amyloid plaques emerge, then the density of those plaques should increase in proportion with how far advanced the disease is. Sure enough, when the team used SWITCH to examine the mammillary bodies of post-mortem human brains at different stages of the disease, they saw exactly that relationship: The later the stage, the more densely plaque-packed the mammillary body was.
“This suggests that human brain alterations in Alzheimer’s disease look similar to what we observe in mouse,” the authors wrote. “Thus we propose that amyloid-beta deposits start in susceptible subcortical structures and spread to increasingly complex memory and cognitive networks with age.”
The team also performed experiments to determine whether the accumulation of plaques they observed were of real disease-related consequence for neurons in affected regions. One of the hallmarks of Alzheimer’s disease is a vicious cycle in which amyloid makes neurons too easily excited and overexcitement causes neurons to produce more amyloid. The team measured the excitability of neurons in the mammillary body of 5XFAD mice and found they were more excitable than otherwise similar mice that did not harbor the 5XFAD set of genetic alterations.
In a preview of a potential future therapeutic strategy, when the researchers used a genetic approach to silence the neurons in the mammillary body of some 5XFAD mice but left neurons in others unaffected, the mice with silenced neurons produced less amyloid.
While the study findings help explain much about how amyloid spreads in the brain over space and time, they also raise new questions, Huang said. How might the mammillary body affect memory and what types of cells are most affected there?
“This study sets a stage for further investigation of how dysfunction in these brain regions and circuits contributes to the symptoms of Alzheimer’s disease,” he said.
Source: picower.mit.edu

Sunday, May 24, 2020

Preventing Alzheimer D.

Preventing Alzheimer's:  Our lifespan has outpaced our brain's healthspan. Harvard professor of neurology Rudolph Tanzi has been at the leading edge of neuroscience as co-director of the Center for Brain Health at Mass General Hospital.  His work  illuminates the key role of neuroinflammation in Alzheimer's disease and the potential to stop it before symptoms emerge.   Like cholesterol and heart disease, waiting for late-stage disease to initiate statin therapy is too late.  Leveraging primary prevention and early detection modalities (i.e. imaging, polygenenic risk scores, to blood tests & eye-tracking modalities) and an early response will be key.  In Dr. Tanzi's terrific talk at Exponential Medicine 2019, he explores the biology, new therapy approaches, including leveraging 3D brain organoid dish models, to developing an understanding and bring a future with personalized treatment, targeting the right pathology, with the right interventions at the right time. Dr. Tanzi closes with lessons on how to protect your brain, summarized by SHIELD (Sleep, Handling stress, Interaction with others, Exercise, Learning new things, and Diet).
 
 

Wednesday, May 06, 2020

Menopuse and AD

Menopause Predisposes a Fifth of Women to Alzheimer's

NEUROLOGICAL HEALTH
Being female is a risk factor for Alzheimer’s. Why?
By Jena Pincott

Thursday, April 23, 2020

AD - Ultrasound

More evidence ultrasound can help in battle against Alzheimer’s disease Combining focused ultrasound with microbubble treatments weakens the connection between blood-brain barrier cells, effectively allowing for better delivery and absorption of drug treatments..

Alzheimer's biomarker


Taking blood - Copyright: Antonia Reeve/Science Photo LibraryBlood phosphorylated tau 181 as a biomarker for Alzheimer's disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts.

Monday, April 20, 2020

Alzheimer Disease Toll

The Human Toll of Alzheimer's

NEUROLOGICAL HEALTH
Alzheimer’s took my wife’s memory and her life and tortured our family. There was nothing we—or medicine—could do to stop it 
By Joel Shurkin

Friday, April 17, 2020

Alzheimer’s Dementia Recognition

A new competition at an international speech A.I. conference hopes to push forward the ability to automatically detect Alzheimer’s dementia after analyzing a clip of a person talking. Startups like Winterlight Labs are also trying to build out this capability.

Thursday, April 09, 2020

Alzheimer Disease

A Multidisciplinary Approach for Addressing Challenges
in Alzheimer’s Disease [Series]
Supported by educational grants from ACADIA Pharmaceuticals Inc.; Allergan; Avanir Pharmaceuticals, Inc.;
and Biogen MA, Inc.
Webcast | Credits: 1.00 | Expires 8/31/2021
Addressing Challenges in Alzheimer's Disease
Atri et al
In a series of brief video segments, experts in neurology, psychiatry, and primary care discuss the diagnosis and treatment of Alzheimer’s disease.
JCP CME | Credits: 1.00 | Expires 12/31/2021
Patient-Centered Care for Alzheimer's Disease
Atri et al
Learn from experts in neurology, psychiatry, neuropsychology, and primary care about working with patients and care partners to create management plans for Alzheimer’s disease that ensure safety, optimize patient autonomy, and minimize agitation and conflict.
Brief Report | Credits: 1.50 | Expires 6/30/2021
Cognitive Assessment for Alzheimer’s Disease
Shaughnessy et al
Meaningful benefits can be derived from the evaluation of cognition in older adults when there is possible cognitive impairment and dementia. In this CME activity, experts explain how brief cognitive assessment tools and neuropsychological evaluations can aid diagnosis and inform a management plan.
Brief Report | Credits: 1.00 | Expires 2/28/2021
Disclosure of Dementia Diagnosis
Goldfarb et al
Disclosing a diagnosis of dementia can be one of the most challenging aspects of care for clinicians. But doing so in a timely fashion benefits patients and their care partners. In this CME activity, learn about using patient-centered communication and following a structured process to disclose the diagnosis.
 Did you know?  
   
 Two analogs of tetrabenazine are recommended as treatment for tardive dyskinesia in the updated American Academy of Neurology guidelines and are FDA-approved for this indication. 
Find out more